AN ORAL, INFLAMMATION-TARGETING AND RESPONSIVE TACROLIMUS FORMULATION FOR THE TREATMENT OF STEROID-REFRACTORY AND STEROID-DEPENDENT INFLAMMATORY BOWEL DISEASE

$3,299,610FY2020Department of the ArmyDOD

Alivio Therapeutics Inc

Investigators